SCHEMBL13664171

SCHEMBL13664171

N#Cc1c(C(=O)c2ccc(C(F)(F)F)cc2)nn(-c2ccc(Cl)cc2)c1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 3/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA9 Q16790 1/20 0.44
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ORAI1 Q96D31 1/20 0.41
ADORA1 P30542 1/20 0.41
AR P10275 1/20 0.39
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664191 0.90 MAPK14 (0.48) MAPTSMN1; SMN2LMNAKDM4ENPSR1
SCHEMBL13664205 0.89 CA1 (0.44) MAPTSMN1; SMN2LMNAKDM4EHTT
SCHEMBL13664193 0.89 MAPT (0.47) MAPTLMNAKDM4EKMT2AMEN1
SCHEMBL13664190 0.89 MAPT (0.47) MAPTLMNAKDM4EKMT2AMEN1
SCHEMBL13664179 0.88 MAPT (0.50) MAPTSMN1; SMN2LMNAKDM4EHTT
SCHEMBL13664177 0.88 MAPT (0.50) MAPTSMN1; SMN2LMNAKDM4EHTT
SCHEMBL13664223 0.88 MAPT (0.52) MAPTSMN1; SMN2LMNAKDM4EHTT
SCHEMBL13664197 0.87 CA1 (0.48) KMT2ACA1CA2CA4CA9
SCHEMBL13664182 0.86 MAPT (0.51) MAPTSMN1; SMN2LMNAKDM4EHTT
SCHEMBL13664224 0.86 MAPT (0.51) MAPTSMN1; SMN2LMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885SMN1; SMN2 3698/4885LMNA 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.